Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
AssigneesCancer Research Technology Limited, Københavns Universitet
InventorsHenrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
Claims4
A method for the preparation of hybridoma cells, which secrete monoclonal antibodies specific for an immunogenic glycopeptide comprising a GSTA motif, wherein said GSTA motif is O-glycosylated at least at the T-residue or at the S-residue of the GSTA motif comprising:
- immunizing a suitable mammal with said immunogenic glycopeptide;
- fusing antibody-producing cells of said mammal with cells of a continuous cell line;
- cloning the hybrid cells obtained in the fusion;
- and
- selecting cell clones secreting the desired antibodies.
Dependencies are inferred from the claim text.